Genelux

GNLX Lead: Phase 3 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Catalyst timeline

Olvi-Vec NSCLC Ph2 interim2026Olvi-Vec NSCLC Ph2 interim, 2026, notable
Olvi-Vec SCLC Ph2 interim2026Olvi-Vec SCLC Ph2 interim, 2026, notable
Olvi-Vec OnPrime Ph3 topline2H 2026Olvi-Vec OnPrime Ph3 topline, 2H 2026, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Olvi-Vec

olvimulogene nanivacirepvec · GLV-1h68 · GL-ONC1

Gene Therapy

Platinum-Resistant/Refractory Ovarian Cancer Phase 3 intraperitoneal NCT02759588
Non-Small Cell Lung Cancer Phase 2 intravenous Newsoara NCT06463665
Small Cell Lung Cancer Phase 1 Phase 1b/2 trial intravenous Newsoara NCT07136285

Technology platforms

CHOICE

Proprietary selection technology and discovery/development platform based on a collection of vaccinia virus (VACV) strains selected on multiple in vitro and in vivo criteria; generates oncolytic VACV immunotherapy candidates for multiple solid tumor types in monotherapy and combination settings

Biotech Distilled coverage (2)

2026-08-14 UPDATE: Genelux (GNLX) - The Fuel Gauge Meets the Catalyst 🔒 Paid
2026-07-15 Genelux Corporation (GNLX) — Scientific Deep Dive for Olvi-Vec and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.